A novel tool for studying D3 receptors and cocaine reward

研究 D3 受体和可卡因奖励的新工具

基本信息

  • 批准号:
    8829450
  • 负责人:
  • 金额:
    $ 19.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-02-01 至 2017-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Memories of drug experience and drug-associated environmental cues can elicit drug-seeking and taking behaviors. There are no effective medications for treating relapse in cocaine addicts. Dopamine (DA) mediates reward-related learning and drugs of abuse can change reward circuits in the brain mesolimbic DA system. DA D3 receptors are preferentially expressed in limbic regions. We and others have used D3 receptor mutant mice and D3 receptor-selective antagonists to demonstrate that these receptors are a major mediator of the rewarding effects of cocaine. Despite its key role in mediating the neurobiological effects of cocaine, medications directly targeting D3 receptors, however, are still limited to preclinical studies. Targeting D3 receptors requires precise knowledge on how D3 receptors contribute to all aspects of drug-induced behaviors and pharmacological ligands with improved D3 receptor specificity. The vast majority of studies so far have attempted to pharmacologically attenuate reinstatement to drug-seeking. We have obtained new preliminary results suggesting that reconsolidation and extinction of cue-cocaine memories may provide alternative action windows for D3 receptor-based therapies. The objective of this developmental proposal is to initiate studies to expand our knowledge on potential new ways to reduce craving and relapse by better understanding and targeting D3 receptor-mediated mechanisms. We propose to engineer and characterize a novel mouse model in which levels of D3 receptors can be up- or down-regulated in the brain. We will then use this mouse model, together with pharmacological methods and the intravenous cocaine self-administration paradigm, to investigate the hypothesis that manipulating D3 receptor levels or activity reduces cocaine- seeking by interrupting the reconsolidation and accelerating the extinction of drug-induced reward memory. The proposed work will have a high impact in that the results will lay important groundwork for developing novel D3 receptor-based therapies in humans, for validating and improving utilities of new D3 receptor agonists and antagonists in reducing relapse, and for investigating how D3 receptors contribute to vulnerability to developing cocaine-seeking and to other cocaine-induced behaviors in the future.
描述(由申请人提供):药物经验的记忆和药物相关的环境线索可以引发药物寻求和服用行为。没有有效的药物治疗可卡因成瘾者的复发。多巴胺(DA)介导奖赏相关学习,药物滥用可改变中脑边缘DA系统的奖赏回路。DA D3受体优先在边缘区表达。我们和其他人已经使用D3受体突变小鼠和D3受体选择性拮抗剂来证明这些受体是可卡因奖赏效应的主要介体。尽管它在介导可卡因的神经生物学作用中起着关键作用,但是直接靶向D3受体的药物仍然是 仅限于临床前研究。靶向D3受体需要精确了解D3受体如何促进药物诱导行为的各个方面以及具有改善的D3受体特异性的药理学配体。到目前为止,绝大多数研究都试图减少重新吸毒。我们已经获得了新的初步结果,提示可卡因记忆的重新巩固和消退可能为基于D3受体的治疗提供替代作用窗口。这项发展提案的目的是启动研究,通过更好地理解和靶向D3受体介导的机制,扩大我们对减少渴望和复发的潜在新方法的了解。我们建议设计和表征一种新的小鼠模型,其中D3受体的水平可以在大脑中上调或下调。然后,我们将使用该小鼠模型,连同药理学方法和静脉内可卡因自我给药范例,来研究操纵D3受体水平或活性通过中断再巩固和加速药物诱导的奖赏记忆的消退来减少可卡因寻求的假设。拟议的工作将产生很大的影响,因为这些结果将为开发新的基于D3受体的人类疗法奠定重要的基础,验证和改善新的D3受体激动剂和拮抗剂在减少复发方面的效用,并调查D3受体如何有助于发展可卡因寻求和其他可卡因诱导的行为。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ming Xu其他文献

Ming Xu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ming Xu', 18)}}的其他基金

Targeting p21-Highly Expressing Cells to Increase Lifespan and Healthspan in Old Age
靶向 p21 高表达细胞以延长老年寿命和健康寿命
  • 批准号:
    10419157
  • 财政年份:
    2022
  • 资助金额:
    $ 19.75万
  • 项目类别:
Targeting p21-Highly Expressing Cells to Increase Lifespan and Healthspan in Old Age
靶向 p21 高表达细胞以延长老年寿命和健康寿命
  • 批准号:
    10627939
  • 财政年份:
    2022
  • 资助金额:
    $ 19.75万
  • 项目类别:
Targeting P21-Highly-Expressing Senescent Cells In Vivo for Improving Cognitive Function in the Alzheimers Diseases
体内靶向高表达 P21 的衰老细胞可改善阿尔茨海默病的认知功能
  • 批准号:
    10394412
  • 财政年份:
    2021
  • 资助金额:
    $ 19.75万
  • 项目类别:
Targeting P21-Highly-Expressing Senescent Cells In Vivo for Improving Cognitive Function in the Alzheimers Diseases
体内靶向高表达 P21 的衰老细胞可改善阿尔茨海默病的认知功能
  • 批准号:
    10196320
  • 财政年份:
    2021
  • 资助金额:
    $ 19.75万
  • 项目类别:
Reciprocal Modulation of the Microbiome and Cellular Senescence in Metabolic Dysfunction
代谢功能障碍中微生物组和细胞衰老的相互调节
  • 批准号:
    10661517
  • 财政年份:
    2020
  • 资助金额:
    $ 19.75万
  • 项目类别:
Targeting p21-positive Senescent Cells in vivo for Alleviating Metabolic and Physical Dysfunction
靶向体内 p21 阳性衰老细胞以减轻代谢和身体功能障碍
  • 批准号:
    10599277
  • 财政年份:
    2020
  • 资助金额:
    $ 19.75万
  • 项目类别:
Targeting p21-positive Senescent Cells in vivo for Alleviating Metabolic and Physical Dysfunction
靶向体内 p21 阳性衰老细胞以减轻代谢和身体功能障碍
  • 批准号:
    10383716
  • 财政年份:
    2020
  • 资助金额:
    $ 19.75万
  • 项目类别:
Reciprocal Modulation of the Microbiome and Cellular Senescence in Metabolic Dysfunction
代谢功能障碍中微生物组和细胞衰老的相互调节
  • 批准号:
    10441563
  • 财政年份:
    2020
  • 资助金额:
    $ 19.75万
  • 项目类别:
Reciprocal Modulation of the Microbiome and Cellular Senescence in Metabolic Dysfunction
代谢功能障碍中微生物组和细胞衰老的相互调节
  • 批准号:
    10259812
  • 财政年份:
    2020
  • 资助金额:
    $ 19.75万
  • 项目类别:
Extinction of cue-elicited cocaine seeking
线索引发的可卡因寻求消失
  • 批准号:
    7803636
  • 财政年份:
    2009
  • 资助金额:
    $ 19.75万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 19.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 19.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 19.75万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 19.75万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 19.75万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 19.75万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 19.75万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 19.75万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 19.75万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 19.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了